The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

Passage Bio, a US-based genetic medicine developer that counts pharmaceutical firm Eli Lilly and conglomerate Access Industries as investors, has closed its initial public offering at more than $248m.

The company floated at the end of last month, raised an initial $216m from 12 million shares issued on the Nasdaq Select Global Market and priced at $18.00 each. The underwriters have purchased 1.8 million additional shares to add $32.4m.

Founded in 2017, Passage Bio is working on genetic therapies…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?